Across 4,437 NHANES III participants followed a median 27.4 years, lean MASLD with metabolic syndrome-related abnormalities (high blood pressure, glucose, triglycerides, low HDL) showed higher all-cause mortality than cryptogenic steatotic liver disease (fat in the liver with no metabolic criteria met) and overweight-only MASLD (BMI ≥ 25 without those abnormalities). Neither of the latter two differed significantly from healthy controls in BMI-based models. Substituting the weight-adjusted waist index for BMI made overweight-only MASLD look worse than controls. Fatty liver is not one risk category. The abnormalities that accompany it appear to matter more than the liver fat or body weight alone. A lean person with fatty liver who also has elevated glucose, blood pressure or lipids may be falsely reassured by a normal BMI. The WWI result is a caution about adiposity measurement: BMI misses central fat distribution, so the apparent safety of overweight-only MASLD may partly reflect misclassification. Limits are real: a single baseline assessment decades ago, steatosis likely defined by ultrasound with imprecision, modest subgroup sizes, and residual confounding. The findings are observational and cannot show that treating abnormalities lowers mortality, though that is the plausible implication. This is confirmatory work consistent with earlier NAFLD data showing metabolic comorbidity, not liver fat itself, drives much of the excess risk. In practice, anyone with fatty liver, lean or not, should have blood pressure, glucose and lipids checked and managed.